Zhaoke Ophthalmology-B (06622.HK) Surges Over 7% on Distribution Deal with Indonesian Pharma PT Ferron for Presbyopia Drug BRIMOCHOL™ PF

According to the Zhongtong Finance APP, Zhaoke Ophthalmology-B (06622) surged over 7%. As of press time, it rose by 7.64%, trading at HK$3.38, with a turnover of HK$2.3893 million.

On the news front, on the evening of November 6, Zhaoke Ophthalmology announced that the company had signed a distribution and supply agreement targeting the Indonesian market with PT Ferron Par Pharmaceuticals (“PT Ferron”), a leading pharmaceutical company in Indonesia, for BRIMOCHOL™ PF, one of the company’s core products used to treat presbyopia. This drug was licensed from Tenpoint Therapeutics, Ltd. Under the terms of the agreement, Zhaoke Ophthalmology granted PT Ferron exclusive rights to import, promote, distribute, market, and sell the product in Indonesia. Zhaoke Ophthalmology will receive an upfront payment and is eligible for additional milestone payments based on certain achievements.

In addition, Tenpoint Therapeutics, the partner of Zhaoke Ophthalmology and the developer of BRIMOCHOL™ PF, announced in June 2025 that the U.S. Food and Drug Administration (FDA) had accepted the drug's New Drug Application (NDA) and set the Prescription Drug User Fee Act (PDUFA) date for January 28, 2026.